Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall cell lung carcinoma

Abstract

BACKGROUND: The objective of this secondary analysis was to identify patients with selected stage IIIB/IV nonsmall cell lung carcinoma and good performance status who were at high risk for requiring subsequent palliative thoracic radiotherapy after initial treatment with first-line chemotherapy. METHODS: The authors conducted a pooled analysis of patients at a single institution who enrolled onto 10 prospective phase 2 and 3 clinical trials that involved first-line, platinum-based chemotherapy. Baseline lung-related characteristics before trial enrollment were analyzed as possible prognostic factors for freedom from pulmonary events (defined either as subsequent thoracic radiation or as a new collapsed lung, which is an indication for thoracic radiation). RESULTS: Of 244 consecutive patients who were reviewed, 42 patients received a palliative course of thoracic radiation, 40 exhibited evidence of new lobar collapse on follow-up chest imaging, and 14 received thoracic radiation for lobar collapse. On univariable analysis, pulmonary symptoms (P =.043) or pneumonia at presentation (P =.0001), increasing size of hilar disease (P 3 cm (hazard ratio, 1.8; P =.003) and prechemotherapy pneumonia (hazard ratio, 2.1; P =.009) were associated with pulmonary events; patients who had both risk factors or hilar disease >5 cm in greatest dimension exhibited a >50% risk of subsequent events. CONCLUSIONS: Patients with bulky hilar disease and a history of pneumonia at presentation were at high risk for requiring palliative thoracic radiation. The authors propose studying these patients to determine whether early thoracic radiation may be beneficial by preserving quality of life and performance status. Cancer 2011. © 2011 American Cancer Society. Hilar disease that measures >3 cm in greatest single dimension and a history of pneumonia at diagnosis predict the need for palliative thoracic radiotherapy after first-line, platinum-based chemotherapy for incurable stage IIIB/IV nonsmall cell carcinoma. Copyright © 2011 American Cancer Society.